WO2005117584A3 - Improved transmucosal delivery of peptides and proteins - Google Patents

Improved transmucosal delivery of peptides and proteins Download PDF

Info

Publication number
WO2005117584A3
WO2005117584A3 PCT/US2005/001440 US2005001440W WO2005117584A3 WO 2005117584 A3 WO2005117584 A3 WO 2005117584A3 US 2005001440 W US2005001440 W US 2005001440W WO 2005117584 A3 WO2005117584 A3 WO 2005117584A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
enhancing
peptides
compositions
absorption
Prior art date
Application number
PCT/US2005/001440
Other languages
French (fr)
Other versions
WO2005117584A2 (en
Inventor
John Ong
Robert Jennings
Christopher Rhodes
Gregg Stetsko
Original Assignee
Amylin Pharmaceuticals Inc
John Ong
Robert Jennings
Christopher Rhodes
Gregg Stetsko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/017456 external-priority patent/WO2005000222A2/en
Application filed by Amylin Pharmaceuticals Inc, John Ong, Robert Jennings, Christopher Rhodes, Gregg Stetsko filed Critical Amylin Pharmaceuticals Inc
Priority to US11/628,123 priority Critical patent/US20090069226A1/en
Publication of WO2005117584A2 publication Critical patent/WO2005117584A2/en
Publication of WO2005117584A3 publication Critical patent/WO2005117584A3/en
Priority to US14/570,295 priority patent/US20150157725A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.
PCT/US2005/001440 2004-05-28 2005-01-12 Improved transmucosal delivery of peptides and proteins WO2005117584A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/628,123 US20090069226A1 (en) 2004-05-28 2005-01-12 Transmucosal delivery of peptides and proteins
US14/570,295 US20150157725A1 (en) 2004-05-28 2014-12-15 Transmucosal delivery of peptides and proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2004/017456 WO2005000222A2 (en) 2003-05-30 2004-05-28 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
USPCT/US2004/017456 2004-05-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/628,123 A-371-Of-International US20090069226A1 (en) 2004-05-28 2005-01-12 Transmucosal delivery of peptides and proteins
US14/570,295 Continuation US20150157725A1 (en) 2004-05-28 2014-12-15 Transmucosal delivery of peptides and proteins

Publications (2)

Publication Number Publication Date
WO2005117584A2 WO2005117584A2 (en) 2005-12-15
WO2005117584A3 true WO2005117584A3 (en) 2006-03-16

Family

ID=35463275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001440 WO2005117584A2 (en) 2004-05-28 2005-01-12 Improved transmucosal delivery of peptides and proteins

Country Status (1)

Country Link
WO (1) WO2005117584A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
WO2000041546A2 (en) * 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
WO2000041546A2 (en) * 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof

Also Published As

Publication number Publication date
WO2005117584A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005000222A3 (en) Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2005117584A3 (en) Improved transmucosal delivery of peptides and proteins
WO2006024275A3 (en) Glp-1 and exendin related invention
MX2009002999A (en) Protease resistant insulin analogues.
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
SI1859041T1 (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
HK1088840A1 (en) Stable analogs of glp-1 glp-1
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
HK1201437A1 (en) Sustained local anesthetic composition containing saib saib
WO2005115441A3 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
EA200701065A1 (en) INJECTABLE COMPOSITIONS CONTAINING NANODISPERS Olanzapine
WO2003064619A3 (en) Long-acting hormone and growth factor compositions and uses thereof
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
WO2005067893A3 (en) Pharmaceutical compositions comprising midazolam in a high concentration
WO2004104018A3 (en) Compositions for delivering peptide yy and pyy agonists
WO2009146024A8 (en) Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
IL177529A0 (en) Stable injectable diclofenac compositions
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
EP1604662A8 (en) 1-¬(3R)-Amino-4-(2-fluoro-phenyl)-butyl|-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
WO2007133944A3 (en) Topical administration of acyclovir
NO20080552L (en) GLP-1 Pharmaceutical Compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11628123

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase